Transforming growth factor-β1 attenuates junctional adhesion molecule-A and contributes to breast cancer cell invasion

Eur J Cancer. 2012 Dec;48(18):3475-87. doi: 10.1016/j.ejca.2012.04.016. Epub 2012 May 28.

Abstract

Transforming growth factor-β1 (TGF-β1) is a potent regulator in promoting the invasion and proliferation of breast cancer cells. Junctional adhesion molecule-A (JAM-A) is a tight junction protein that displays an inverse relationship to cell invasiveness in breast cancer cells. Whether TGF-β1 signaling induces alteration of JAM-A expression leading to cell invasion has not been investigated. In this study, we report that TGF-β1 down-regulated JAM-A expression via its effect on both transcriptional and post-translational regulations of JAM-A, thus inducing cell invasion. On exploring whether TGF-β1 might be the upstream regulator of JAM-A expression, we found that knockdown of TGF-β receptors and canonical Smad signaling could upregulate JAM-A level and inhibit cell invasion in MDA-MB-231 cells. TGF-β1 treatment of MCF-7 cells caused a significant reduction of JAM-A mRNA and protein and induced cell invasion. Delineating the signal mechanisms involved in TGF-β1-mediated JAM-A repression, we found that TGF-β1 significantly inhibited JAM-A gene transcription via the activation of Smads. In addition to Smad activation, we found that involvement of p54 JNK is crucial for post-translational modification of TGF-β1-mediated JAM-A protein degradation. Blockage of JNK pathway by inhibitor could attenuate TGF-β1-induced cell invasion. We provide evidences for the first time that TGF-β1 induces breast cancer cell invasion via TGF-β1-mediated control on JAM-A expression. Identification of JAM-A as a downstream target of TGF-β1 represents a crucial mechanism in cancer progression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / pathology*
  • Breast Neoplasms / pathology*
  • Cell Adhesion Molecules / antagonists & inhibitors*
  • Cell Adhesion Molecules / biosynthesis
  • Cell Adhesion Molecules / genetics
  • Cell Line, Tumor
  • Chromatin Immunoprecipitation
  • Clathrin / antagonists & inhibitors
  • Clathrin / genetics
  • Collagen
  • Dactinomycin / pharmacology
  • Down-Regulation
  • Drug Combinations
  • Female
  • Humans
  • JNK Mitogen-Activated Protein Kinases / physiology
  • Laminin
  • Neoplasm Invasiveness
  • Neoplasm Proteins / biosynthesis
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / physiology*
  • Protease Inhibitors / pharmacology
  • Protein Processing, Post-Translational / drug effects
  • Proteoglycans
  • RNA Interference
  • RNA, Messenger / metabolism
  • RNA, Neoplasm / metabolism
  • RNA, Small Interfering / pharmacology
  • Receptors, Cell Surface / antagonists & inhibitors*
  • Receptors, Cell Surface / biosynthesis
  • Receptors, Cell Surface / genetics
  • Receptors, Transforming Growth Factor beta / antagonists & inhibitors
  • Smad Proteins / antagonists & inhibitors
  • Smad Proteins / biosynthesis
  • Smad Proteins / genetics
  • Smad Proteins / physiology
  • Transcription, Genetic
  • Transforming Growth Factor beta1 / physiology*
  • Ubiquitination / drug effects

Substances

  • Cell Adhesion Molecules
  • Clathrin
  • Drug Combinations
  • F11R protein, human
  • Laminin
  • Neoplasm Proteins
  • Protease Inhibitors
  • Proteoglycans
  • RNA, Messenger
  • RNA, Neoplasm
  • RNA, Small Interfering
  • Receptors, Cell Surface
  • Receptors, Transforming Growth Factor beta
  • Smad Proteins
  • Transforming Growth Factor beta1
  • matrigel
  • Dactinomycin
  • Collagen
  • JNK Mitogen-Activated Protein Kinases